MBMarion Bertho

Marion Bertho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marion Bertho has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Patsouris

    Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Paul Papin, Angers, France

    2 shared publications
  • Anne Jaffré

    Department of Medical Information, Institut Bergonié, Bordeaux, France

    1 shared publication
  • Anthony Goncalves

    Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

    1 shared publication
  • Christelle Levy

    Department of Medical Oncology, Centre François Baclesse, Caen, France

    1 shared publication
  • Cyriac Blonz

    Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Pays de la Loire, France

    1 shared publication
  • David Pérol

    Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

    by Marion Bertho, Julien Fraisse, Anne Patsouris, Paul Cottu, Monica Arnedos, David Pérol, Anne Jaffré, Anthony Goncalves, Marie-Paule Lebitasy, Véronique D’hOndt, et al.

    Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Using the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO versus non-BO MBC at diagnosis, with adjustment on main prognostic factors using a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1), describe treatment patterns, and estimate factors associated with OS. Out of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2−), n = 4 102/13,229 (31%); HER2+, n = 644/3909 (16.5%); HR−/HER2−, n = 295/2 957 (10%)]. BO MBC patients had a better adjusted OS compared with non-BO MBC [52.1 months (95% confidence interval (CI) 50.3–54.1) versus 34.7 months (95% CI 34.0–35.6) respectively]. The 5-year OS rate of BO MBC patients was 43.4% (95% CI 41.7–45.2). They also had a better PFS1 [13.1 months (95% CI 12.6–13.8) versus 8.5 months (95% CI 8.3–8.7), respectively]. This observation could be repeated in all subtypes. BO disease was an independent prognostic factor of OS [hazard ratio 0.68 (95% CI 0.65–0.72), p < 0.0001]. Results were concordant in all analyses. BO MBC patients have better outcomes compared with non-BO MBC, consistently, through all MBC subtypes.


  • A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer

    by Marion Bertho, Anne Patsouris, Paule Augereau, Marie Robert, Jean-Sebastien Frenel, Cyriac Blonz, Mario Campone

    Introduction: In most cases, metastatic breast cancer remains an incurable disease. A PIK3CA mutation is detected in 30–40% of all hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancers. PIK3CA activating mutations have been linked to endocrine resistance. PI3K inhibitors therefore offer promising new therapeutic options for this disease. Areas covered: This review discusses the pharmacologic properties, preclinical development, clinical efficacy, and safety profile of alpelisib, a PI3K inhibitor indicated in HR+/HER2– PIK3CA-mutated advanced breast cancer, describing current therapeutic indication and open questions. Expert opinion: Following results of the SOLAR-1 trial, alpelisib became the first PI3K inhibitor approved by the U.S. Food and Drug Administration, in combination with fulvestrant, for postmenopausal women and men with HR+/HER2– PIK3CA-mutated advanced breast cancer following progression on or after an endocrine-based regimen. This trial showed a substantial improvement in progression-free survival. However, given the side effects of alpelisib, the treatment decision should follow a thorough benefit-risk assessment. The BYLieve trial suggests alpelisib-fulvestrant benefit after progression on CDK 4/6 inhibitors. The identification of patients that are likely to benefit the most from PI3K inhibitors is still eagerly sought.